Explanation of Pfizer: “Uruguay had priority to receive vaccines”



[ad_1]

MONTEVIDEO.- “Uruguay did a great job of negotiating, both with us and with the parent company and had a specific priority for the administration of doses», Declared Mariel Peric to the Uruguayan newspaper El País, which led the negotiation by Pfizer with the Uruguayan government for the arrival of doses of the vaccine against the coronavirus.

Uruguay, which yesterday beat its record for daily Covid-19 infections by registering 1238 new cases and also that of people with the disease, with 9,261 assets, according to the latest report from the National Emergency System (Sinae), began negotiations with Pfizer last December. In January 2021, he then signed the contract.

The Pfizer-BioNtech vaccine against the coronavirus
The Pfizer-BioNtech vaccine against the coronavirus Ahmad Gharabli – AFP

“The truth is that the work has been extremely collaborative on the part of the presidency and the Ministry of Public Health (MSP). And that is why we are moving quickly through the process so that the first doses have arrived, ”he said.

When asked why Uruguay has priority, Peric replied that the process has always been very nimble from the start of the negotiations. “The good thing was that we got the government to receive the amount of doses stipulated in the agreed schedule,” he said.

When El País wanted to know what conditions the Uruguayan laboratory had put in place to conclude the agreement, Peric stressed that they were “similar conditions in all countries of the world”, but that he could not give specific details of the contract due to the confidentiality agreement.

“It has been learned that Argentina and Brazil have been solicited for sovereign assets as collateral for possible future litigation,” El País insisted, but Peric said he could not provide information.

Finally, the representative of Pfizer said the laboratory will ensure that the 2 million doses they would reach the country in due course.

El País / GDA newspaper

THE NATION

More information



[ad_2]
Source link